Correction to: Improvements in Cognitive Processing Speed, Disability, and Patient ‑Reported Outcomes in Patients with Early Relapsing‑Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4‑year, Real‑World, Open‑Label Study

ConclusionThese results further extend our knowledge of the effectiveness, specifically regarding improvements in cognitive processing speed, disability and PROs, of long-term natalizumab treatment in early RRMS patients.Clinicaltrials.govNCT01485003 (5 December 2011)

http://link.springer.com/10.1007/s40263-022-00982-6

Source: CNS Drugs - February 13, 2023 Category: Neurology Source Type: research